ERBB2 and neoplasm: A preclinical study investigating CAR-T cell therapy targeting HER2 that included a CD28 costimulatory domain and a PD-1 blocking domain showed limited cytokine production, suggesting a low risk of systemic toxicity and off-tumor leakage [74].